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Primary adrenal insufficiency is life threatening and can present alone or in combination
with other comorbidities. Here, we have described a primary adrenal insufficiency syndrome
and steroid-resistant nephrotic syndrome caused by loss-of-function mutations in
sphingosine-1-phosphate lyase (SGPL1). SGPL1 executes the final decisive step of the
sphingolipid breakdown pathway, mediating the irreversible cleavage of the lipid-signaling
molecule sphingosine-1-phosphate (S1P). Mutations in other upstream components of the
pathway lead to harmful accumulation of lysosomal sphingolipid species, which are
associated with a series of conditions known as the sphingolipidoses. In this work, we have
identified 4 different homozygous mutations, c.665G>A (p.R222Q), c.1633_1635delTTC
(p.F545del), c.261+1G>A (p.S65Rfs*6), and c.7dupA (p.S3Kfs*11), in 5 families with the
condition. In total, 8 patients were investigated, some of whom also manifested other
features, including ichthyosis, primary hypothyroidism, neurological symptoms, and
cryptorchidism. Sgpl1–/– mice recapitulated the main characteristics of the human disease
with abnormal adrenal and renal morphology. Sgpl1–/– mice displayed disrupted
adrenocortical zonation and defective expression of steroidogenic enzymes as well as renal
histology in keeping with a glomerular phenotype. In summary, we have identified SGPL1
mutations in humans that perhaps represent a distinct multisystemic disorder of sphingolipid
metabolism.
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Introduction
Primary adrenal insufficiency (PAI) is most commonly congen-
ital in children. Manifestations can include hyperpigmentation, 
failure to thrive, and a poor response to illness, with hypogly-
cemia and hypotension. Reduced life expectancy is described, 
and the condition can be fatal if undetected. It is genetically 
heterogeneous, with some gene defects causing syndromic 
disease. Mechanisms of disease include steroid biosynthetic 
defects, adrenocorticotropic hormone (ACTH) resistance, 
adrenal dysgenesis, cholesterol synthesis disorders, and meta-
bolic disorders incorporating peroxisomal and mitochondrial 
defects (reviewed in refs. 1, 2). Our group has previously iden-
tified a number of genes in adrenal insufficiency syndromes 
(3–8); however, within our patient cohort (n > 350), the genetic 
cause is currently unknown for 38% of cases, rendering their 
prognosis uncertain.
We investigated one extended, consanguineous kindred 
with 4 affected individuals with PAI, 2 of whom also had ste-
roid-resistant nephrotic syndrome, described as focal segmen-
tal glomerulosclerosis (FSGS) (9) (Figure 1, kindred 1). Inheri-
tance was suggestive of an autosomal recessive pattern, and we 
used whole-exome sequencing (WES) to investigate. Mutations 
identified in a candidate gene were then sought in the remain-
der of our cohort and in patients manifesting FSGS alone.
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accessed July 2016), with a minor allele frequency of greater than 
0.01; and (iv) evaluating nonsynonymous coding variants, splice 
variants, and indels only. Finally, candidate variants in 2 genes 
(Chr10:69957117C>T in MYPN and Chr10:72628151G>A in 
SGPL1) were investigated for segregation with disease in the kin-
dred by Sanger sequencing. Both variants segregated with disease 
in the family. MYPN encodes myopalladin, which is expressed 
in striated muscle and functions as a structural, signaling, and 
gene expression regulatory molecule in response to muscle stress. 
Variants in MYPN have previously been implicated in dilated car-
diomyopathy, not a clinical finding in our patients, and although 
rare (allele count 69/121208), there are 2 homozygotes noted in 
ExAC for this variant. Thus, we demoted this variant in MYPN and 
focused on the variant in SGPL1. This variant, Chr10:72628151G>A 
c.665G>A; p.R222Q, has a minor allele frequency of 1.656e-5; this 
represents 2/120744 alleles reported in the ExAC browser. Both 
are heterozygotes; one is from the South Asian population and the 
other non-Finnish European. No homozygotes are annotated in 
any database (see dbSNP; ExAC; National Heart, Lung, and Blood 
Institute [NHLBI] Exome Sequencing Project [ESP], Exome Vari-
ant Server, http://evs.gs.washington.edu/EVS/).
Results
Human genetic findings. The index case, patient 1, was diagnosed 
with an isolated glucocorticoid deficiency at age 8 months, when he 
presented with genital hyperpigmentation. He subsequently devel-
oped steroid-resistant nephrotic syndrome with biopsy findings of 
FSGS at 2.5 years and received a kidney transplant at age 5 years 
(9). A younger sibling with similar clinical history (not sequenced) 
died at age 4 years, while an older sibling, at 8 years, and a cousin, 
at 3 years, only have PAI (9) (Figure 1, kindred 1; Table 1).
Affected individuals were mutation negative for the known 
genetic causes of PAI (3). WES was carried out for 2 affected indi-
viduals in the pedigree (patients 2 and 3; Figure 1). SNPs, with a 
threshold coverage of at least 10 reads on the respective nucleo-
tides, were assessed using Ingenuity Variant Analysis (http://
www.ingenuity.com/products/variant-analysis; detailed descrip-
tion in Methods). In brief, the number of variants was reduced 
by the following strategy: (i) identifying variants that were com-
mon to both individuals; (ii) excluding variants that were het-
erozygous; (iii) removing variants, annotated in SNP databases 
(dbSNP, http://www.ncbi.nlm.nih.gov/SNP/, release 85; Exome 
Aggregation Consortium [ExAC], http://exac.broadinstitute.org, 
Figure 1. Pedigrees of kindreds 1 to 5 where all affected individuals manifested PAI, with or without SRNS, and were positive for mutations in SGPL1. 
Black symbols indicate individuals with PAI alone, half-filled in green indicate those who additionally had steroid-resistant nephrotic syndrome, and green 
indicate those with SRNS alone. All affected individuals were homozygous for the indicated mutations (patients sequenced have been numbered from 
1 to 8), and parents were heterozygous (those sequenced denoted by gray symbols). Mutations for patients 2, 3, and 5 were identified by WES and the 
remainder by Sanger sequencing of SGPL1.
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We subsequently identified further mutations in SGPL1 in 
5 affected patients with a background of PAI from 4 additional 
families using whole-exome or Sanger sequencing (Figure 1, kin-
dreds 2–5; Table 1). In 4 out of these 5 patients, PAI was also asso-
ciated with a steroid-resistant nephropathy. In all cases, patients 
SGPL1 encodes sphingosine-1-phosphate lyase (SGPL1), an 
important ER enzyme in sphingolipid catabolism (reviewed in refs. 
10, 11). SGPL1 executes the final decisive step of the sphingolipid 
breakdown pathway, initiating irreversible cleavage of the lipid-
signaling molecule sphingosine-1-phosphate (S1P) (Figure 2A).
Figure 2. p.R222Q and p.F545del mutations affect highly conserved areas in SGPL1 and are loss of function, resulting in proteins with reduced lyase activity. 
(A) SGPL1 regulates flow of the sphingolipid biochemical intermediates (in green) and carries out the final degradation step in the pathway. (B) Partial align-
ment of SGPL1 protein sequences, generated by Clustal Omega (48), showing conservation of arginine (R) at position 222 and phenylalanine (F) at position 
545, highlighted in yellow, with numbering relative to human sequence. For all but the most distant organisms, these amino acids are conserved. Alignment 
source accession numbers from ENSEMBL are as follows: Homo sapiens, human, ENSP00000362298; Mus musculus, mouse, ENSMUSP00000112975; Rattus 
norvegicus, rat, ENSRNOP00000070983; Tetraodon nigroviridis, pufferfish, ENSTNIP00000016065; Xenopus laevis, clawed frog, ENSXETP00000017960; Ciona 
intestinalis, sea squirt, ENSCINP00000002369; Drosophila melanogaster, fruit fly, FBpp0086158; Caenorhabditis elegans, nematode, B0222.4; and Saccharo-
myces cerevisiae, yeast, YDR294C. Sequence conservation is beneath the alignment. Asterisks indicate total conservation; colons indicate partial conservation. 
(C) SGPL1 activities were measured in lysates of Sgpl1–/– mouse fibroblasts. **P < 0.01, 2-tailed Student’s t test (n = 3). (D) Lysates of Sgpl1–/– mouse fibroblasts 
expressing WT or the mutant SGPL1 (25 μg protein/lane) were analyzed by immunoblotting for the presence of the FLAG-tagged protein (representative image, 
n = 3). (E) SGPL1 mRNA expression in a human tissue panel, analysis using the 2–ΔΔCT algorithm (n = 3). S intestine, small intestine.
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patient 8, also had marked adrenal androgen deficiency (serum 
dehydroepiandrosterone sulphate level <3 mcg/dl [normal range 
(NR) 26–460]; androstenedione <1 ng/ml [NR 0.5–4.7]). Adre-
nal imaging was undertaken in some of the patients. Patient 5 
had normal appearance of the adrenals on ultrasound and MRI 
(undertaken at ages 0.5 years and 5.9 years, respectively). Patient 
6 and patient 7 were both reported to have imaging suggestive of 
calcifications in the adrenals (imaging undertaken at age 1 year 
and 0.6 years, respectively), with patient 6 additionally reported 
to have bilateral enlarged adrenal glands.
The nephrotic syndrome was steroid resistant and was pres-
ent in 5 patients and manifested between the ages of 1.5 months 
and 5.5 years (Figure 1 and Table 1). Biopsy findings were con-
sistent with FSGS in all affected patients (Supplemental Table 2; 
further details for patients 1 and 5–7). Electron microscopy of the 
renal biopsy from patient 5 showed cellular vacuolizations and 
partial effacement of podocytes (Supplemental Figure 1; elec-
tron microscopy of renal biopsy for patient 5). Patients 1, 6, and 8 
were post–renal transplant, while patients 5 and 7 were awaiting 
transplantation at the time of this writing. Patient 8, age 17.5 years, 
redeveloped proteinuria at 12 years following her initial transplan-
tation at 5 years, necessitating a second renal transplant, a graft 
biopsy having shown graft failure from chronic rejection.
Extraadrenal and -renal effects are described within our 
cohort. Generalized ichthyosis was present in most, though not 
all, patients (Table 1 and Supplemental Figure 2). Skin biopsies 
conducted in patients 6 and 7 demonstrated a thinned epidermis 
with hyperkeratosis and decreased granular layer. Primary hypo-
thyroidism was reported in 4 of the patients requiring treatment 
with l-thyroxine (patients 5–8). Thyroid peroxidase antibodies 
were negative in all cases.
Neurodegenerative disease is seen in several of the sphin-
golipidoses associated with accumulating sphingolipid metabo-
lites. Here, progressive motor and cognitive decline is described 
for 3 patients (patients 5, 6, and 7), with ataxia and sensorineu-
ral hearing loss also reported (patients 5 and 6) (Table 1). Both 
Peruvian siblings (patients 6 and 7) initially presented with 
development appropriate for age. However, during follow-up, 
impaired acquisition of new skills was reported. Patient 6 had 
loss of speech and developed progressive hypotonia and trun-
cal ataxia; at age 8.4 years, this patient was no longer walking. 
Following development of ataxia at 8 years, cranial MRI showed 
contrast enhancement of cerebellar structures among other fea-
tures. Patient 5 was reported to have had normal development 
as assessed by the Denver II developmental screening test (18) 
at age 2.3 years. However, assessment at age 4.3 years showed 
delayed gross motor, language, and social skills. Aged 6 years at 
the time of this writing, she has developed mild gait abnormali-
ties associated with ataxia. Serial cranial MRI highlighted the 
progressive nature of her disease (Supplemental Figure 3); at 4.3 
years, contrast enhancement was seen in the bilateral globus pal-
lidus, medial thalamic nucleus, and central pons (not observed in 
a previous scan at 8 months). Ophthalmological findings in this 
patient included “salt and pepper” retinopathy, cranial nerve III 
to IV synkinesia, ptosis, and esotropia affecting the right eye. 
She had complex partial seizures. None of the above-mentioned 
patients were reported to have autonomic dysfunction. The old-
were homozygous for the change and unaffected parents were 
heterozygous. The c.665G>A (p.R222Q) mutation seen in kin-
dred 1 was also identified in patient 4 (kindred 2), who present-
ed with PAI at 18 months. Interestingly, the R222Q mutations 
in kindreds 1 and 2 have arisen independently; 2 synonymous 
exonic (rs827249 and rs865832) and 2 intronic (rs41315008 and 
rs923177) SNPs, within SGPL1 itself and surrounding the muta-
tion, differed between patients in these kindreds (Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI90171DS1). In kindred 3, a female (patient 5) pre-
sented with PAI at 6 months, developing nephrotic syndrome on 
follow-up at age 5.5 years. Patient 5 and her parents underwent 
WES and analysis through the GOSgene pipeline (12). Under a 
homozygous recessive model, the only rare variant that segregat-
ed with the disease was an in-frame deletion, c.1633_1635delTTC 
in SGPL1. Kindred 4 comprised 2 affected siblings (patients 6 
and 7), manifesting PAI and nephrotic syndrome (< 1 year for 
both), who had a canonical splice site change (c.261+1G>A; 
p.S65Rfs*6). Patient 8, presenting with nephropathy (<1 year) 
and later developing PAI, had a frameshift mutation (c.7dupA; 
p.S3Kfs*11). We believe that the mutations in kindreds 3, 4, and 
5 were novel and have not been annotated in any database. Con-
currently, exome data from a cohort of 200 pediatric patients 
presenting with FSGS alone was examined for SGPL1 mutations, 
but none were identified. The frameshift and splice site muta-
tions, p.S3Kfs*11 and p.S65Rfs*6, respectively, are predicted to 
result in markedly truncated mRNA message and are likely to be 
destroyed by nonsense-mediated mRNA decay, suggesting that 
the phenotype results from loss of enzyme activity and may rep-
resent a new defect of sphingolipid metabolism. The mutations 
p.R222Q and p.F545del are within highly conserved residues 
and are predicted to cause disruption to vital, highly conserved 
eukaryotic protein domains (Figure 2B). To reveal whether the 
mutants possessed residual lyase activity, the mutated proteins 
were expressed in Sgpl1–/– mouse fibroblasts. The activity of both 
mutants was close to zero (Figure 2C). The mutations also appear 
to affect expression or possibly stability of the protein, with both 
the p.R222Q and p.545del detected at the expected size but in 
lower amounts than the WT on immunoblotting (Figure 2D).
In agreement with previous studies, SGPL1 was ubiquitously 
expressed in human tissues, with moderate levels in the adrenal 
cortex and kidneys (Figure 2E), consistent with rat and mouse 
expression profiles (13–15). High levels were noted in the testes 
and thyroid (Figure 2E). Mutations in other components of the 
sphingolipid breakdown pathway lead to harmful accumulation of 
lysosomal sphingolipid species, which is associated with a spec-
trum of conditions known as the sphingolipidoses (16). These 
include Niemann-Pick disease, Gaucher disease, and Fabry dis-
ease, among others, which are multisystemic and often progres-
sive. While a renal phenotype is described in some of these condi-
tions (17), adrenal disease has not been reported to date.
Human clinical findings. In our patients, PAI was common to 
all affected individuals presenting in infancy, with the exception 
of patient 8, who presented at age 9 years. For most, this was an 
isolated glucocorticoid deficiency necessitating hydrocortisone 
replacement; 2 patients additionally had mineralocorticoid defi-
ciency (Table 1). The only postpubertal patient within the cohort, 
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est patient in this cohort (patient 8 at 17.5 years), however, had no 
intellectual disability and normal neurological findings, includ-
ing a normal brain MRI (conducted at 11 years).
Fasting lipid profiling revealed raised total cholesterol and 
triglycerides in some of the patients (Table 1), though in all cas-
es, sampling was conducted with diagnosis of nephrotic syn-
drome. Mass spectrometric analysis of serum from patient 5 (with 
p.F545del) revealed increased S1P and ceramide species in com-
parison with an age- and sex-matched control (Supplemental Fig-
ure 4), which would fit with our hypothesis that this disease alters 
sphingolipid metabolism.
Persistent lymphopenia was a reported feature in 2 of our 
patients (Table 1). This has been most extensively investigated 
in patient 5, with lymphocyte subset analysis revealing low CD3+ 
and low naive CD4+ and naive CD8+ cells, but normal proliferative 
capacity (Supplemental Tables 3 and 4). Neither of these patients 
had an increased frequency of infections.
Undervirilization was reported in patient 6, who had micro-
penis, right cryptorchidism, and bilateral microorchidism, associ-
ated with low serum anti-Müllerian hormone, suggesting that par-
tial gonadal dysfunction may be part of the clinical picture.
Sgpl1–/– mouse adrenal histology and renal histology; expression of 
SGPL1 in human adrenals. SGPL1 is highly conserved, with human 
SGPL1 sharing 84% identity and 92% similarity to mouse SGPL1 
(14, 19). The mutations are predicted to be loss-of-function; hence, 
the Sgpl1–/– mouse could provide a model for the disorder. We 
investigated the phenotype of the Sgpl1–/– mouse, both our own 
findings and previous reports in the literature, and compared this 
with the clinical findings in our patients (Table 2). Sgpl1–/– mice 
are born normally, but fail to thrive at around 2 weeks of age. 
Most die within the first few weeks of weaning; the reason for 
this is unknown (20–22). While Sgpl1–/– mice are reported to have 
impaired testicular and ovarian steroidogenesis and are infertile 
(23), an adrenal phenotype has not previously been investigated.
In our study of mouse adrenals, cortical zonation was found 
to be compromised in 10-day-old Sgpl1–/– mice regardless of sex, 
with less definition between zona glomerulosa (ZG) and zona fas-
ciculata (ZF), and between ZF and X-zone (Figure 3A). Cells in the 
corticosterone-producing ZF were smaller, contained fewer lipid 
droplets, and had a higher degree of eosinophilia. Compromised 
development of the X-zone is seen in other mouse models of adre-
nal insufficiency, including those with Sf1 mutations (24), sug-
gesting that SGPL1 may also have a role to play in the developing 
human adrenal. Disruption in steroidogenesis was supported by 
the analysis of steroidogenic enzymes in the adrenal tissue from 
these mice. Sgpl1–/– adrenals showed lower expression of cyto-
chrome P450 side-chain cleavage (CYP11A1), the first enzyme in 
the steroidogenic cascade, while the classical pattern of subcapsu-
lar clusters of aldosterone synthase (CYP11B2) staining present in 
Sgpl1+/+ mice was replaced by a more continuous pattern in adre-
nals from Sgpl1–/– mice (Figure 3B).
Adrenal glands from affected patients were not available for 
study, but Western blotting confirmed the presence of SGPL1 in 
normal human adrenals; 3 immunoreactive bands were observed 
in lysates of adrenals and HEK293-overexpressing SGPL1, indi-
cating the specificity of our antibody in detecting SGPL1 (Figure 
3C). SGPL1 was expressed in the human fetal adrenal (HFA) at all 
stages analyzed, namely Carnegie stage 19 (approximately 46th 
day) and Carnegie stage 22 (approximately 53rd day) (Figure 3D). 
At a later stage (18 weeks), when the fetal and definitive zones 
(which later constitute the ZG, ZF, zona reticularis [ZR]) are distin-
guishable, SGPL1 was found to be expressed in both (Figure 3D). 
In the adult human adrenal, SGPL1 immunoreactivity was seen 
throughout the cortex, with the highest signal in the ZR, respon-
sible for adrenal androgen secretion, and very little expression in 
the medulla and capsule (Figure 3E).
Consistent with previous reported findings in SGPL1-defi-
cient mice (21, 25), we saw mesangial hypercellularity and pro-
teinaceous casts in the tubules of Sgpl1–/– mice, with overall histo-
logical appearances supporting a glomerular phenotype (Figure 
4, A–H). Moreover, a higher degree of glomerular fibrosis was 
observed in kidneys from Sgpl1–/– mice using Masson’s trichrome 
stain (Figure 4, D and H).
Discussion
This is the first instance of SGPL1 deficiency in humans highlight-
ing a novel biochemical player involved in adrenal disease. The 
sphingolipids form one of the major classes of the mammalian lip-
Table 2. Comparison of SGPL1-deficient mouse phenotype with clinical findings in the patients
Adrenal  
pathology
Nephrotic  
disease
Ichthyosis Primary 
hypothyroidism
Abnormal  
neurology
Lymphopenia Dyslipidemia
Patient 1A + + – – – – –
Patient 2A + – – – – – –
Patient 3A + – – – – – –
Patient 4 + – – – – + –
Patient 5 + + + + + + –
Patient 6 + + + + + – +
Patient 7 + + + + + – +
Patient 8 + + + + – – +
SGPL1-deficient miceB  
(with associated references)
+  
(see Results)
+  
(see Results; ref. 25)
+  
(24)
–  
(Not reported)
–  
(Not reported)
+  
(22, 39)
+  
(30)
AClinical phenotype as published by Ram et al., 2012 (9). BAs compared with clinical findings in our patients, full extent of SGPL1-deficient mouse 
phenotype is not included in table, see Discussion. +, feature reported; –, feature not reported.
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Figure 3. Adrenals from Sgpl1–/– mice show histological abnormalities, and SGPL1 is expressed in human adrenals. (A and B) Adrenals from Sgpl1–/– mice 
show histological abnormalities. (A) H&E staining of Sgpl1+/+ and Sgpl1–/– adrenals. Note the less defined morphological zonation in the Sgpl1–/– adrenals 
compared with that from Sgpl1+/+ mice. Moreover, the characteristic lipid droplets found in the ZF (arrowheads in top-right panel) and visible as large areas 
in the cytoplasm devoid of eosin staining (as lipids are extracted during the paraffin-embedding procedure) are strongly reduced in Sgpl1–/– adrenals  
(n = 3). Cap, capsule. Scale bars: 100 μm (left); 25 μm (middle); 5 μm (right). (B) CYP11A1 and CYP11B2 expression in Sgpl1+/+ and Sgpl1–/– adrenals. CYP11A1 
staining in Sgpl1–/– adrenals is less prominent compared with Sgpl1+/+, while the characteristic patchy expression of aldosterone synthase (CYP11B2) is lost 
in Sgpl1–/– adrenals (n = 3). Scale bars: 100 μm (top); 25 μm (bottom). (C–E) Expression of SGPL1 in human adrenals. (C) Western blotting of lysates from 
human adrenal, HEK293, cells and HEK293 cells overexpressing SGPL1 probed with anti-SGPL1 antibody (representative image of n = 3). (D) SGPL1 expres-
sion in the HFA at 19 and 22 Carnegie (Carn) stage as well as at 18 weeks showing widespread expression (n = 1 each). FZ, fetal zone; DZ, definitive zone. 
Scale bars: 100 μm. (E) SGPL1 expression in the human adult adrenal (n = 3). Note the stronger expression of SGPL1 in the ZR compared with ZG and ZF, 
while the capsule and medulla (M) are negative. Scale bars: 100 μm (left panel); 25 μm (right 3 panels).
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nal gland zonation together with a reduction in expression of 
steroidogenic enzymes and loss of vacuolization in the ZF are con-
sistent with the biochemical finding of adrenal hormone insuffi-
ciency in patients. Significant SGPL1 expression is observed in 
the kidney by analysis of β-galactosidase expression in organs 
dissected from male and female SGPL1 reporter mice, with spe-
cific patterns of expression in the cortex, medulla, and papilla 
(13). Images from The Human Protein Atlas (http://www.protein-
atlas.org/) show SGPL1 expression in the tubules and glomeruli 
in normal human adult kidney; within the glomerulus, staining 
is apparently predominantly in podocytes (see Supplemental Fig-
ure 5). Sgpl1–/– mice have previously been reported to have renal 
defects, with increased blood urea levels (21), and a renal pheno-
type was confirmed in our studies, with histological changes in 
the kidney matching the human biopsy results. Inducible SGPL1 
deficiency in mice and pharmacological inhibition of SGPL1 in 
rats both cause podocyte-based kidney toxicity, with glomerular 
proteinuria (25). Increased mesangial matrix with obliteration of 
some capillary lumina is seen in the SGPL1-deficient mouse mod-
el with podocyte effacement on electron microscopy (25).
Additionally, ichthyosis, disordered lipid metabolism, and 
lymphodepletion are shared in some patients with the mouse, 
whereas the neurological deficits and hypothyroidism have not 
been noted in mice. It is feasible that some of the clinical findings 
in patients are attributable to alternative gene defects, given the 
high degree of consanguinity within the pedigrees.
Ceramide species constitute 50% of the lamellar membrane 
of the stratum corneum and play an important role in maintain-
ing skin barrier function (32). Ichthyosis is also seen in Gau-
cher disease type 2, where substantial reductions in lysosomal 
β-glucocerebrosidase lead to excess glucosylceramides and 
decreased ceramides, imbalance of which is postulated to contrib-
ute to the barrier abnormality (33). In the skin of partially depleted 
SGPL1 mice, a rise in S1P concentrations is seen with a reduction 
in ceramide concentrations that may in turn interfere with barrier 
idome. They have multiple roles: some as structural components 
of cell membranes (sphingomyelin, glycosphingolipid) and others 
as signaling molecules (ceramide, sphingosine, S1P). S1P has auto-
crine, paracrine, and distant effects, regulating cell migration, dif-
ferentiation, survival, and other complex physiological processes 
by activating a subgroup of G protein–coupled receptors referred 
to as S1P1–5. SGPL1, an intracellular ER enzyme, carries out the 
final decisive step of the pathway with degradation of intracellular 
S1P, regulating flow of the sphingolipid biochemical intermedi-
ates, and therefore has a key role in cell metabolism and determin-
ing cell fate (Figure 2A).
Lipids, including sphingolipids, have been shown to control 
steroid hormone biosynthesis in adrenal glands. Sphingolipid 
intermediates ceramide and sphingosine have been demon-
strated to reduce steroidogenesis in vitro (26–28). Sphingosine 
has been reported to interact directly with the orphan nuclear 
receptor steroidogenic factor-1 (SF-1; NR5A1), which plays a role 
in both the acute phase of steroidogenesis and in adrenal and 
gonadal development (28). In binding to SF-1, sphingosine main-
tains the transcription factor in an inactive conformation. The 
sphingosine intermediate S1P, however, has been demonstrated 
to induce transcription of several steroidogenic factors (29). 
Thus, sphingolipid intermediates may have some role in modu-
lating steroidogenesis and potentially adrenal development. We 
saw increased plasma S1P and ceramide levels in patient 5, and 
we anticipate that SGPL1 deficiency would lead to cytosolic accu-
mulation of sphingolipid intermediates. Studies of tissues from 
SGPL1-deficient mice demonstrate an accumulation of S1P (22, 
25, 30). While S1P is largely considered a proproliferative signal-
ing molecule and ceramide proapoptotic in normal physiology, 
studies have demonstrated that pathological accumulation of S1P 
in the cytosol can induce apoptosis (31).
In contrast with what occurs in the mouse, SGPL1 deficiency 
is not lethal in humans, but in many aspects, the mouse pheno-
type mirrors the human condition. In the mouse, imperfect adre-
Figure 4. Histological features of the glomeruli. (A–C) H&E staining of Sgpl1+/+ kidney showing normal cortical histology (A) and glomeruli with open capil-
lary loops and normal cellularity (B and C, yellow arrowhead). The kidneys from Sgpl1–/– mice (E–G) have mild mesangial hypercellularity with glomerular 
hypertrophy (F and G, yellow arrowhead) and large protein casts in the tubules (white arrows). (D and H) Masson’s trichrome stain. Kidneys from Sgpl1–/– 
mice (H) show increased glomerular fibrosis (red stain) compared with Sgpl1+/+ (D). n = 3 in all cases. Scale bars: 100 μm (A and E); 25 μm (B–D and F–H).
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Since strategies to modify SGPL1 activity are being explored 
in preclinical and clinical trials of several conditions, including 
multiple sclerosis and rheumatoid arthritis (40, 41), further char-
acterization of SGPL1 deficiency in human disease may provide 
important insights into the potential long-term effects of modulat-
ing this pathway in patients.
Methods
WES. WES using the Illumina HiSeq 2000 Sequencer was conducted 
on 2 affected individuals (patients 2 and 3) (samples processed by Oto-
genetics Corp.). WES samples were prepared as an Illumina sequenc-
ing library, and in the second step, the sequencing libraries were 
enriched using the Agilent V4 Enrichment Kit. The captured libraries 
were sequenced and downstream analysis conducted via DNAnexus 
(https://www.dnanexus.com/) and Ingenuity variant analysis. SNPs 
with threshold coverage of at least 10 reads on the respective nucleo-
tides were assessed.
Confidence filter. For confidence, call quality was set to be at least 
20, read depth at least 10 in any sample; only data outside 0.1% of 
most exonically variable 100-base windows in healthy public genomes 
and outside 0.1% of most exonically variable genes in healthy public 
genomes (1000 Genomes, http://www.internationalgenome.org/, 
EXAC) were included.
Common variants. Common variants were filtered out by exclud-
ing those observed with an allele frequency of at least 0.5% in any of 
the 1000 Genomes, EXAC, and all of the NHLBI exomes.
Predicted deleterious changes. Predicted deleterious changes were 
defined as those that are disease associated according to computed 
American College of Medical Genetics and Genomics (ACMG) guide-
lines classification (42), being pathogenic or likely pathogenic or asso-
ciated with loss of function of a gene being frameshift, in-frame indel, 
or start/stop codon change, missense, or splice-site change up to 2 
bases into the intron.
Genetic analysis. Variants were included if they were homozygous in 
both cases and excluded if they were homozygous, compound heterozy-
gous, hemizygous, heterozygous, haploinsufficient, or het-ambiguous. 
Variants were excluded if they were present in hetero- or homozygosity 
in 2 or more control subjects analyzed on the same platform.
PCR and sequencing. Each exon of genes of interest, including 
intronic boundaries, was amplified by PCR using specific primers 
(primer sequences, Supplemental Table 5). The reaction mixture con-
tained 100 ng DNA template, 1× PCR buffer, 200 μM each dNTP, 
200 nM each primer, and 1 U Taq DNA polymerase (Sigma-Aldrich). 
Cycling conditions were as follows: 95˚C for 5 minutes (1 cycle); 95˚C 
for 30 seconds, 55˚C for 30 seconds, and 72˚C for 30 seconds (30 
cycles); and 72˚C for 5 minutes. PCR products were visualized on 1% 
agarose gel and sequenced using the ABI Prism Big Dye Sequencing 
Kit and an ABI 3700 automated DNA sequencer (Applied Biosystems) 
in accordance with the manufacturer’s instructions.
Quantitative real-time PCR. The expression of SGPL1 and GAP-
DH mRNA was investigated using a panel of cDNAs derived from 16 
adult tissues (adrenal cortex, kidney, liver, testes, ovary, colon, small 
intestine, brain, thymus, adipose tissue, heart, lung, thyroid, skeletal 
muscle, bladder, placenta).
Quantitative reverse-transcriptase PCR (RT-PCR) was set up in 
duplicate (per sample) on a Stratagene Mx3000P thermocycler using 
KAPA SYBR Fast qPCR Master Mix with 200 nM forward and reverse 
function (25). The phenotype in these mice is one of acanthosis 
(epidermal hyperplasia) with orthokeratotic hyperkeratosis.
We observed high levels of SGPL1 in human thyroid tissue 
(Figure 2E) and 4 of the patients had primary hypothyroidism; 
however, mild disruptions of thyroid function are a reported phe-
nomenon with PAI, particularly in the context of untreated dis-
ease (34–36). Additionally, proteinuria, particularly in nephrotic 
syndrome, often results in the urinary loss of thyroid hormones 
with associated binding proteins, resulting in a reduction in serum 
total thyroid hormone levels (37). This is generally equilibrated by 
increasing the free fraction of the hormones, though patients with 
a low thyroid reserve may develop hypothyroidism consequent to 
this urinary loss.
Progressive neurological disease was reported in 3 of our 
patients, but has not been reported in Sgpl1–/– mice. Curiously, 
compared with other organs, SGPL1 expression is low in rat and 
mouse brain (13, 15). Within the brain, SGPL1 shows a distinct 
expression pattern, with highest activity in the olfactory bulb in 
mouse (15, 38). Other regions with higher expression are the hip-
pocampus (P.P. Van Veldhoven, unpublished observations) and 
Purkinje cells in the cerebellum (13, 31). Neuroanatomical stud-
ies in the cerebellum demonstrate that neurons here are the first 
to degenerate in SGPL1-deficient mice (31). A calpain-mediated 
neurotoxic mechanism has been proposed relating to pathological 
accumulation of cytosolic S1P in SGPL1 deficiency (31).
Sgpl1–/– mice exhibit an extensive range of other phenotypes, 
including skeletal (osteopetrosis and dysfunctional osteoclasts), 
pulmonary (proteinaceous exudates in alveoli impairing gas 
exchange), cardiac (increased interstitial cellularity and myo-
cardium vacuolation), urinary tract (urothelial cells affected by 
widespread ballooning vacuolation, degeneration, and apopto-
sis), thymic (atrophy), and hepatic abnormalities (disruption of 
liver homeostasis with defective hepatic lipid metabolism) (22, 
30, 39). Hematological abnormalities associated with lyase defi-
ciency in the mouse model include platelet activation and lym-
phodepletion, which occurs as a consequence of the disruption of 
the S1P gradient between lymphoid tissues and blood (normally 
high to low, respectively). This leads to reduced T cell egress into 
the blood (22, 39). Similarly, platelet abnormalities and lympho-
penia were reported in some of our patients (Table 1). Inhibition 
of SGPL1 in healthy subjects has also been demonstrated to cause 
a decrease in peripheral T cell numbers (22). Partial restoration 
of S1P lyase in human knockin mouse lines (expressing 1 or 2 nor-
mal human alleles and less than 10% and 20% of normal lyase 
activity, respectively) confers full protection from lesions in the 
lung, bone, urinary tract, and heart that develop in SGPL1 null 
mice (22). Lymphodepletion, however, still occurs in the partially 
rescued human knockin mouse line.
In conclusion, we have identified a potentially progressive, 
disorder incorporating PAI and nephrotic syndrome, among other 
features. SGPL1 deficiency in humans has multisystemic effects, 
although the precise impact on sphingolipid metabolism and con-
sequent pathogenic mechanism is yet to be elucidated and is likely 
to be tissue specific. Our findings highlight the importance of the 
sphingolipid metabolic pathway in adrenal function. A genetic diag-
nosis for patients with this form of PAI will be important for correct 
treatment, genetic counseling, and screening for comorbidities.
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Generation and validation of mouse lines. Heterozygous Sgpl1–/+ ani-
mals, obtained as described before (20, 43, 46) and bred to a C57BL/6 
background, were crossed to obtain Sgpl1–/– pups. Animals were housed 
in the animal facility of KU Leuven.
Human and mouse histology. Human adult adrenals, mouse adrenals, 
and kidneys from Sgpl1+/+ and Sgpl1–/– mice were fixed in 4% paraformal-
dehyde (Sigma-Aldrich) and embedded in paraffin. HFAs were obtained 
from the MRC–Wellcome Human Development Biology Resources 
(HDBR) – Institute of Genetics Medicine, Newcastle, United Kingdom). 
Sections were obtained using a microtome (Microm HM 325, Thermo 
Fisher) at 6-μm thickness, deparaffinized, treated with 3% hydrogen 
peroxide in PBS for 30 minutes, and then, depending on the primary 
antibody (see below), treated or not with 10 mM sodium citrate, pH 
6.0, for 20 minutes at 95oC in a water bath. Sections were then blocked 
with 5% normal goat serum (Sigma-Aldrich) in PBS 0.1% Triton X-100 
(T-PBS) and incubated overnight with anti-CYP11B2 (a gift from Celso 
Gomez-Sanchez, University of Mississippi, Oxford, Mississippi, USA, 
1:200 in PBS, with previous antigen unmasking), anti-CP11A1 (D8F4F, 
Cell Signaling, 1:200 in PBS, without previous antigen unmasking), and 
anti-SGPL1 (105183, AbCam, 1:200 in PBS, without previous antigen 
unmasking). Sections were washed in T-PBS and incubated with a bio-
tinylated goat anti-primary IgG secondary antibody (BA-9200 and BA-
1000,Vector Laboratories) diluted 1:500 in T-PBS for 2 hours. Sections 
were washed, treated with avidin-biotin complex (ABC Elite Kit, Vec-
tor Laboratories) according to the manufacturer’s instructions, rinsed 
again, and incubated with the ImmPACT DAB peroxidase substrate kit 
(Vector Laboratories). The reaction was stopped with H2O, and slides 
were counterstained with hematoxylin, dehydrated, and coverslipped 
using Vecta Mount (Vector Laboratories).
H&E staining was performed using standard procedures. For 
fibrotic changes in the kidney, Masson’s trichrome staining kit (Sigma-
Aldrich) was employed. Images were acquired using a Leica DM5500B 
microscope equipped with a DCF295 camera (Leica) and DCViewer 
software (Leica), and then processed with Adobe Photoshop CS6 and 
Adobe Illustrator CS6.
Statistics. In studies in which statistical analyses were performed, 
a 2-tailed Student’s t test was used to generate P values. P values less 
than or equal to 0.05 were considered significant. Data are presented 
as mean ± SD in all figure parts in which error bars are shown.
Study approval. This study was approved by the local hospital ethics 
committees, and all parents (and children, when possible) gave written 
informed consent. Approval was obtained from the Outer North East 
London Research Ethics Committee, reference number 09/H0701/12, 
the Marmara University Ethics Committee, reference number 
B.30.2.MAR.0.01.02/AEK/108, and the Vall d’Hebron Hospital Eth-
ics Committee (Paediatric Endocrinology Collection at Vall d’Hebron 
Biobank). All experiments involving mice were approved by the Ethical 
Committee for Animal Experimentation (ECD) of KU Leuven (project 
P196/2012, granted to PPVV; laboratory license number LA1210260).
Note added in proof. Since the submission of this paper, SGPL1 
deficiency has been described as the cause of Charcot-Marie-Tooth 
neuropathy in 2 siblings (47).
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were cultured in MEM-Eagle medium with 10% FBS, 2 mM ultragluta-
mine-1, and 0.2% Mycozap. Cells were transfected with SGPL1 vectors 
by electroporation (Neon Transfection System) using the parameters 
described for SV40-transformed MEF and a 10-μl microporator tip 
(44). Per plasmid tested, 3 aliquots of 10 μl transfected cells (~5 × 105 
cells) were seeded in a 90-mm dish. Two days after transfection, cells 
were collected by trypsinisation, centrifuged, and washed with PBS. 
The pelleted cells, stored at –20°C till use, were adjusted to approxi-
mately 250 μl, with 0.25 M sucrose, 5 mM MOPS, pH 7.2, 1 mM EDTA, 
and 0.1% (v/v) ethanol, and sonicated (Hielscher Ultrasonic tissue 
homogenizer UP50H; 3 pulses of 50 W) on ice. Lyase was measured as 
described before (45), with small modifications. The activity represents 
the amount of hexadecanal formed from sphinganine-1-phosphate and 
is corrected for endogenous levels; values are given in pmol substrate 
converted per minute per mg lysate protein (pmol/min/mg protein).
Western blotting. HEK-293 cells were transfected with the SGPL1 
vector using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. After 48 hours, cells were lysed in RIPA buf-
fer (Sigma-Aldrich) supplemented with complete protease inhibitors 
(Roche) and lysates cleared by centrifugation at 13,000 g for 10 min-
utes at 4 °C; supernatants were added to an equal volume of reducing 
Laemmli loading buffer 2× (Sigma-Aldrich). Normal adult adrenals (n 
= 3) were placed in tubes with RIPA buffer supplemented with com-
plete protease inhibitors and lysates obtained using a Precellys24 
Tissue Homogenizer via bead beating technology. Lysates were then 
cleared and prepared as above. Samples were heated at 95–100˚C for 
5 minutes and size-separated on 4%–12% SDS-PAGE gels (NuPage, 
Thermo Scientific). Proteins were then transferred to nitrocellulose 
membrane (GE Healthcare Life Sciences) using a semi-dry transfer 
blot (Bio-Rad) at 15 V for 1 hour. Blots were blocked with 5% nonfat 
dry milk in PBS–Tween 0.1% (blocking buffer) and immunolabeled 
overnight with a polyclonal anti-SGPL1 antibody (105183, Abcam, 
at 1:1000 in blocking buffer). The following day, the membrane was 
washed 3 times in PBS–Tween 0.1% and then incubated with a goat 
anti-rabbit IRDye 800 (926–6871, LI-COR) at a 1:5,000 dilution, 
washed again, and visualized using the LI-COR Odyssey System.
For visualization of SGPL1 in transfected mouse fibroblasts, 
lysates were size separated as above and membranes incubated with 
anti-FLAG antibodies (200472-21, Roche), followed by alkaline phos-
phatase–conjugated secondary antibody (A2429, Sigma-Aldrich). 
NBT/BCIP (Roche) was used for chromogenic detection.
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